| |
 The
Chris Elliott Fund for Glioblastoma Brain Cancer Research (CEF)
is a fund raising effort supporting cutting edge glioblastoma
research and care. 100% of CEF's proceeds received go to high
grade astrocytoma and glioblastoma brain cancer research,
education, and advocacy outreach programs.
CEF supports research at the Dana-Farber Cancer Institute, a
world leader in cancer research and care and Harvard
University affiliate. Our team of Medical Advisors include Dr.
Ronald DePinho, Director of the Center For Applied Cancer
Science, Dr. Lynda Chin, Associate Professor, Department of
Medical Oncology, and Dr. Patrick Wen, Clinical Director,
Dana-Farber/Brigham and Women's Cancer Center.
The CEF has raised $330,000 in direct funds and another
$600,000 in grants for brain cancer research, advocacy and
education. Specifically, the CEF raises funds for the Dana
Farber Cancer Institute in Boston and more specifically, for
the Applied Cancer Science Center and the Christopher S.
Elliott Neuro-oncology Lab for Glioblastoma Brain Cancer
Research. The CEF lobbies in WA, DC and meets with countless
organizations and families who have a loved one diagnosed with
GBM. What the CEF provides most is hope.
In six short years, the Chris Elliott Fund for Glioblastoma
Brain Cancer Research has been credited and published for
funding a portion of the research that has:
-
Lead to the discovery of the genes that mutate and cause high grade
astrocytomas and glioblastoma, which the inspired a large-multi-center
effort across the US and other countries to determine all of the
alterations in human cancer (Human Genome Project), beginning with
glioblastoma.
-
Funded a portion of the research at the DFCI/Center for Applied Cancer
Science resulting in the discovery of distinct molecular and clinical
glioblastoma subtypes proving that current standard treatment protocol
for this disease is ineffective.
-
Funded a portion of the research that has now discovered that several,
rather than just one, cell-growth switches are simultaneously overactive
in many brain tumors and solid tumors, explaining why treatment with
just a single “targeted” switch-blocking drug often yields disappointing
results.
-
Currently funding a portion of the research that is prioritizing these
genes at the Dana Farber Cancer Institute and the National Institute of
Health.
-
Currently funding tests related to the RTK co-activation paradigm in the
clinical setting.
-
Currently funding the evaluation of novel drugs for patients with
malignant gliomas such as PI3kinase and HSP90 Inhibitors.
CEF's fund raising efforts have included a successful golf
tournament, dinner, silent and live auctions, raffles, and
bike ride. The support raised has enabled brain cancer
researchers to make a series of remarkable discoveries that
have helped to define the genetic alterations found in glioblastoma.
At CEF, we are the voice of people living with glioblastoma –
we provide information, resources, and support and most
importantly, we seek the funding to secure a cure!
|
|
